Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Chronic Lymphocytic Leukemia

> Sunday, June 1, 2025 7:00 AM – 8:00 AM CT (8:00 AM – 9:00 AM ET)

> > Faculty Catherine C Coombs, MD William G Wierda, MD, PhD

> > > Moderator Neil Love, MD



#### Faculty



**Catherine C Coombs, MD** Associate Clinical Professor Division of Hematology/Oncology Department of Medicine UCI Health Orange County, California



MODERATOR Neil Love, MD Research To Practice Miami, Florida



#### William G Wierda, MD, PhD

Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey Section Chief, Chronic Lymphocytic Leukemia Center Medical Director Department of Leukemia, Division of Cancer Medicine Executive Medical Director, Inpatient Medical Services The University of Texas MD Anderson Cancer Center Houston, Texas



#### **Contributing Faculty**



John N Allan, MD Associate Professor of Clinical Medicine Weill Cornell Medicine New York, New York



Jeff Sharman, MD Medical Director of Hematology Research Sarah Cannon Research Institute at Willamette Valley Cancer Center Eugene, Oregon




Matthew S Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Leader, Lymphoma Program Dana-Farber/Harvard Cancer Center Director of Clinical Research Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts



Tanya Siddiqi, MD
Medical Director of Lymphoma
City of Hope Orange County
Professor
Department of Hematology and Hematopoietic
Cell Transplantation
Director, Chronic Lymphocytic Leukemia Program
City of Hope
Duarte, California




#### We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



### Clinicians in the Audience, Please Complete the Pre- and Postmeeting Surveys





	Immunotherapy and Antibody-Drug	
	<b>Conjugates in Lung Cancer</b> 11:15 AM - 12:45 PM CT (12:15 PM - 1:45 PM ET)	
Friday May 30	Colorectal Cancer 6:30 PM - 8:30 PM CT (7:30 PM - 9:30 PM ET)	
	EGFR Mutation-Positive Non-Small Cell Lung Cancer 6:30 PM - 8:30 PM CT (7:30 PM - 9:30 PM ET)	
	Urothelial Bladder Cancer 6:45 AM - 7:45 AM CT (7:45 AM - 8:45 AM ET)	
Saturday May 31	Non-Hodgkin Lymphoma 7:00 PM - 9:00 PM CT (8:00 PM - 10:00 PM ET)	
	<b>Prostate Cancer</b> 7:00 PM - 9:00 PM CT (8:00 PM - 10:00 PM ET)	
	Chronic Lymphocytic Leukemia (Webinar) 7:00 AM - 8:00 AM CT (8:00 AM - 9:00 AM ET)	
Sunday June 1	HER2-Positive Gastrointestinal Cancers 7:00 PM - 8:30 PM CT (8:00 PM - 9:30 PM ET)	
	Ovarian and Endometrial Cancer 7:00 PM - 9:00 PM CT (8:00 PM - 10:00 PM ET)	
	<b>Renal Cell Carcinoma (Webinar)</b> 7:00 AM - 8:00 AM CT (8:00 AM - 9:00 AM ET)	
Monday June 2	Multiple Myeloma (Webinar) 6:00 PM - 7:00 PM CT (7:00 PM - 8:00 PM ET)	
	Metastatic Breast Cancer 7:00 PM - 9:00 PM CT (8:00 PM - 10:00 PM ET)	
Tuesday June 3	Soft Tissue Sarcoma and Other Connective Tissue Neoplasms (Webinar) 7:00 AM - 8:00 AM CT (8:00 AM - 9:00 AM ET)	



Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Chronic Lymphocytic Leukemia

> Sunday, June 1, 2025 7:00 AM – 8:00 AM CT (8:00 AM – 9:00 AM ET)

> > Faculty Catherine C Coombs, MD William G Wierda, MD, PhD

> > > Moderator Neil Love, MD



#### Dr Coombs — Disclosures Faculty

Advisory Committees	AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MingSight Pharmaceuticals, Pharmacyclics LLC, an AbbVie Company		
Consulting Agreements	AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Lilly, Octapharma		
Contracted Research	AbbVie Inc, BeiGene Ltd, Carna Biosciences, Lilly		
Speakers Bureaus	AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly		
Stock Options/Stock — Public Companies	Geron Corporation, Pfizer Inc		



#### Dr Wierda — Disclosures Faculty

Consulting Agreements	BeiGene Ltd, Numab Therapeutics AG		
Contracted Research	AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol Myers Squibb, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Nurix Therapeutics Inc, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company		
Nonrelevant Financial Relationships	National Comprehensive Cancer Network (Chair, CLL), Support by the NIH/NCI under award number P30 CA016672 and use of MD Anderson Cancer Center Support Grant (CCSG) shared resources		



#### Dr Allan — Disclosures Survey Participant

Advisory Committees	NeoGenomics	
Consulting Agreements	AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group,Jansse Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company	
Contracted Research	BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group	
Data and Safety Monitoring Boards/Committees	Merck	
Speakers Bureaus	AbbVie Inc, BeiGene Ltd	



#### Dr Davids — Disclosures Survey Participant

Consulting AgreementsAbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Galapagos NV, O member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Lilly Inc, Merck, Nuvalent, Schrödinger, Secura Bio, Takeda Pharmaceuticals Therapeutics Inc	
Contracted Research	Ascentage Pharma, MEI Pharma Inc, Novartis
Nonrelevant Financial Relationships	UpToDate



#### Dr Sharman — Disclosures Survey Participant

Consulting Agreements	AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb,
and Contracted Research	Genentech, a member of the Roche Group, Lilly, Merck



#### Dr Siddiqi — Disclosures Survey Participant

Advisory Committees	AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Celgene Corporation, Gilead Sciences Inc	
Contracted Research	Bristol Myers Squibb	
Data and Safety Monitoring Boards/Committees	BeiGene Ltd	
Speakers Bureaus	AstraZeneca Pharmaceuticals LP	



#### **Dr Love — Disclosures**

**Dr Love** is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.



#### **Commercial Support**

This activity is supported by an educational grant from Lilly.

#### Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.



This educational activity contains discussion of non-FDA-approved uses of agents and regimens. Please refer to official prescribing information for each product for approved indications.



#### Agenda

Module 1: Selection and Sequencing of Therapy for Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda

**Module 2:** First-Line Therapy for CLL — Dr Coombs

**Module 3:** Novel Agents and Strategies for RR CLL — Dr Wierda

Module 4: ASCO and EHA 2025



#### Agenda

Module 1: Selection and Sequencing of Therapy for Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda

**Module 2:** First-Line Therapy for CLL — Dr Coombs

**Module 3:** Novel Agents and Strategies for RR CLL — Dr Wierda

Module 4: ASCO and EHA 2025



#### **Beyond Covalent BTK Inhibitors and Venetoclax**

# Regulatory and reimbursement issues aside, what would be your preferred third-line systemic therapy for a <u>60-year-old</u> patient with double-refractory CLL?

Regulatory and reimbursement issues aside, what would be your preferred third-line systemic therapy for an <u>80-year-old</u> patient with double-refractory CLL?



#### **Beyond Covalent BTK Inhibitors and Venetoclax**

Regulatory and reimbursement issues aside, what second-line systemic therapy would you recommend for a <u>60-year-old</u> patient who has experienced disease progression on a covalent BTK inhibitor and is not a candidate for venetoclax because of comorbidities?

Regulatory and reimbursement issues aside, what second-line systemic therapy would you recommend for an <u>80-year-old</u> patient who has experienced disease progression on a covalent BTK inhibitor and is not a candidate for venetoclax because of comorbidities?



#### **Beyond Covalent BTK Inhibitors and Venetoclax**

Regulatory and reimbursement issues aside, what systemic therapy would you recommend next for a <u>60-year-old</u> patient who has experienced disease progression on venetoclax/obinutuzumab and developed unacceptable tolerability issues (bleeding, arthralgias) on a covalent BTK inhibitor?

Regulatory and reimbursement issues aside, what systemic therapy would you recommend next for an <u>80-year-old</u> patient who has experienced disease progression on venetoclax/obinutuzumab and developed unacceptable tolerability issues (bleeding, arthralgias) on a covalent BTK inhibitor?



## In which line of therapy are you currently using pirtobrutinib for your patients with CLL?

Dr Coombs	Third line
Dr Wierda	Second line and beyond
Dr Allan	Third line
Dr Davids	Third line
Dr Sharman	Third line
Dr Siddiqi	Fourth line



Based on current clinical trial data and your personal experience, how would you compare the global <u>efficacy and tolerability/toxicity</u> of pirtobrutinib to those of ibrutinib, acalabrutinib and zanubrutinib for patients with relapsed/refractory CLL?

	Efficacy	Tolerability/toxicity	
Dr Coombs	There are not enough available data at this time	Pirtobrutinib has the least toxicity	
Dr Wierda	There are not enough available data at this time	Pirtobrutinib has the least toxicity	
Dr Allan	About the same	Pirtobrutinib has the least toxicity	
Dr Davids	There are not enough available data at this time	Pirtobrutinib has the least toxicity	
Dr Sharman	There are not enough available data at this time	Pirtobrutinib has the least toxicity	
Dr Siddiqi	About the same	Pirtobrutinib has the least toxicity	

Based on the published literature and/or your clinical experience, please estimate the percent chance that a patient with CLL who is receiving <u>ibrutinib</u> will experience toxicity during treatment that will require withholding or permanently discontinuing administration.

What is the primary toxicity patients experience that leads to withholding this drug/regimen?

	Chance of withholding	Chance of discontinuation	Primary toxicity
Dr Coombs	50%	40%	Cardiac; myalgias/arthralgias
Dr Wierda	40%	40%	Various
Dr Allan	20%	20%	BTKi class effects
Dr Davids	40%	20%	Atrial fibrillation
Dr Sharman	50%	40%	Arthralgias
Dr Siddiqi	20%	20%	Arthralgias

BTKi = BTK inhibitor

Based on the published literature and/or your clinical experience, please estimate the percent chance that a patient with CLL who is receiving <u>acalabrutinib</u> will experience toxicity during treatment that will require withholding or permanently discontinuing administration. What is the primary toxicity patients experience that leads to withholding this drug/regimen?

	Chance of withholding	Chance of discontinuation	Primary toxicity
Dr Coombs	15%	10%	Headache
Dr Wierda	20%	10%	Various
Dr Allan	15%	15%	BTKi class effects
Dr Davids	20%	10%	Headache
Dr Sharman	20%	10%	Various
Dr Siddiqi	15%	10%	Fatigue

Based on the published literature and/or your clinical experience, please estimate the percent chance that a patient with CLL who is receiving <u>zanubrutinib</u> will experience toxicity during treatment that will require withholding or permanently discontinuing administration. What is the primary toxicity patients experience that leads to withholding this drug/regimen?

	Chance of withholding	Chance of discontinuation	Primary toxicity
Dr Coombs	15%	10%	I've not recognized a predominant toxicity yet
Dr Wierda	20%	10%	Various
Dr Allan	15%	15%	BTKi class effects
Dr Davids	20%	10%	Hypertension
Dr Sharman	25%	10%	Various
Dr Siddiqi	10%	5%	Fatigue

Based on the published literature and/or your clinical experience, please estimate the percent chance that a patient with CLL who is receiving <u>pirtobrutinib</u> will experience toxicity during treatment that will require withholding or permanently discontinuing administration. What is the primary toxicity patients experience that leads to withholding this drug/regimen?

	Chance of withholding	Chance of discontinuation	Primary toxicity
Dr Coombs	5%	5%	Neutropenia; GI
Dr Wierda	15%	5%	Various
Dr Allan	10%	10%	BTKi class effects
Dr Davids	15%	5%	Bleeding
Dr Sharman	10%	10%	Infection
Dr Siddiqi	5%	5%	Bleeding

#### Select Questions on Chimeric Antigen Receptor (CAR) T-Cell Therapy

Are there any differences in the way you think through eligibility in terms of patient age, comorbidities, et cetera for CAR T-cell therapy versus other available treatments?

For patients who are eligible to receive pirtobrutinib and CAR T-cell therapy, which one do you generally recommend first?



#### **Select Questions on CAR T-Cell Therapy**

#### In general, do you use bridging therapy for your patients who are being referred for CAR T-cell therapy? If so, what's your usual treatment approach?

Do you believe patients with RR CLL have been "cured" with CAR Tcell therapy?




#### **Select Questions on CAR T-Cell Therapy**

Based on the published literature and/or your clinical experience, what is the chance that a patient with CLL receiving CAR T-cell therapy will experience CRS? What about ICANS?

What is your approach to monitoring and managing these toxicities?




At what point in the treatment course are you referring patients with multiregimenrelapsed CLL for consultation regarding CAR T-cell therapy?





## To approximately how many patients with CLL have you administered lisocabtagene maraleucel (liso-cel) within or outside of a protocol setting?





## Selection and Sequencing of Therapy for Relapsed/Refractory CLL

## June 1, 2025

#### WILLIAM G. WIERDA MD, PHD

**PROFESSOR OF MEDICINE** 

SECTION HEAD, CLL

DEPARTMENT OF LEUKEMIA

U.T. M.D. ANDERSON CANCER CENTER

HOUSTON, TX USA

## **Targeted Therapy Sequencing for CLL**



#### **Factors affecting timelines:**

- Age
- Del(17p) / *TP53*-m
- IGHV-MS / Del(11q)
- Complex karyotype



## **Selected First-line Phase III Trials in CLL**

		Treatment Arms			
Trial	Ν	Control Investigational			
EA9161	720	IBR + OBIN	IBR + OBIN + VEN		
A041702	454	IBR + OBIN	IBR + OBIN + VEN		
CLL17	909	IBR	VEN + OBIN VEN + IBR		
MAJIC	750	VEN + OBIN	ACA + VEN		
CLL16 (del(17p) / <i>TP53-</i> m / CK)	178	VEN + OBIN	ACA + VEN + OBIN		
CELESTIAL-TNCLL	640	VEN + OBIN	SONRO + ZANU		
BRUIN CLL-313	250	BR	PIRTO		
BRUIN CLL-314	650 <sup>#</sup>	IBR	PIRTO		
CLL18	813	VEN + OBIN	VEN + PIRTO (Fixed)	VEN + PIRTO (uMRD)	
BELLWAVE-011	1200	IBR or ACA	ΝΕΜΤΑ		
BELLWAVE-008	300	FCR/BR	NEMTA		

<sup>#</sup> enrolls both frontline and R/R BTK-naïve CLL

#### **Differentiated Kinase Inhibition Profile**

			TEC Family Kinases			ases	Inhibition of Other Kinases	
5/e		IC <sub>50</sub> (nM)	BTK	ITK	Tec <sup>#</sup>	TXK <sup>*</sup>	BMX*	Notable Target Kinases
rsi		lbrutinib <sup>2</sup>	0.5	10.7	78	2.0 <sup>3</sup>	0.8	>10 more: EGFR family
ever	Ac	alabrutinib <sup>3</sup>	5.1	>1000	93	368	46	Selective
	Za	nubrutinib <sup>4</sup>	0.22	30	1.9	n/a	n/a	N/A (not published)
e int)	Ve	cabrutinib <sup>1</sup>	3	14	14	474	224	Selective -4 non-Tec family kinases: SRC family, NEK11
eversible	Ve Nei Pii	mtabrutinib <sup>5</sup>	4.23	>10000	5.8	36.4	5.23	>20 more: SRC & TRK families, RAF1, MEK1
êVe	Pi	rtobrutinib <sup>6</sup>	3.15	>5000	1234	209	1155	Very Selective
Å,		uxeptinib <sup>7</sup>	8.4	4.3	>1000	n/a	14.5	18 w/ IC <sub>50</sub> <10 nM: FLT3 (wt, ITD) c-MET, TRK family & Aurora kinases

n/a=not available

\* Determined with vecabrutinib free base (also relevant for SRC and EGFR)

<sup>#</sup>Activated (also relevant for LCK)

<sup>1</sup>Neuman et al., ASH 2016

<sup>2</sup> Honigberg et al., PNAS 2010

<sup>3</sup> Byrd et al., NEJM 2016


<sup>4</sup> Tam et al., ASH 2016

<sup>5</sup> Eathiraj et al., Pan Pacific Lymphoma Conference 2016


<sup>6</sup> Brandhuber et al., SOHO 2018

<sup>7</sup> Zhang et al, EHA 2018

## **Pirtobrutinib is a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor**



Pirtobrutinib may stabilize/maintain BTK in a closed inactive conformation<sup>11</sup>



- Pirtobrutinib is approved in the USA to treat relapsed or refractory MCL after at least two lines of systemic therapy, including prior BTK inhibitor<sup>10</sup>
- Inhibits both WT and C481-mutant BTK with equal low nM potency in *in* vitro models<sup>11</sup> and CLL cells<sup>12</sup>
- Steady state plasma exposure corresponding to 96% BTK target inhibition and a pirtobrutinib-BTK binding complex half-life of about 2 hrs

In contrast to cBTKi (A), pirtobrutinib (B) appears to stabilize BTK in a closed, inactive conformation, blocking access to upstream kinases and phosphorylation of Y551, thus inhibiting scaffolding interactions that support kinaseindependent BTK signaling<sup>11</sup>

#### Pirtobrutinib: Progression-Free Survival in CLL/SLL Patients who Received Prior BTKi Treatment

Median prior lines = 3 Median prior lines = 5 100 100 Progression-free Survival Probability (%) 87.4% Median (months) Median (months) 95% CI Censored, n (%) 95% CI Censored, n (%) Progression-free Survival Probability (%) 90 90 83.4% 19.6 16.9-22.1 126 (51) 16.8 13.2-18.7 44 (44) 80 **80** · 68.9% 70 -70 60.9% 60 -60 56.2% **50** · 50 42.2% **40** 40 30 30 20 20 10 10 0 0 22 28 32 22 24 26 28 10 12 16 18 20 24 26 30 34 36 14 10 12 16 20 30 32 34 36 14 18 Months from First Dose Number at risk Months from First Dose Number at risk 38 33 21 12 247 228 215 202 182 162 144 113 103 82 57 46 22 60 50 8 3 0 19 79 70 3

Median follow-up of 19.4 months for patients who received prior BTKi


 Median follow-up of 18.2 months for patients who received prior BTKi and BCL2i

**Prior BTKi and BCL2i patients** 


All prior BTKi patients


#### Mato et al. ASH 2022, Abstract #961

#### Pirtobrutinib: Progression-Free Survival in CLL/SLL Subgroups BTK C481 mutation status<sup>a,b</sup>




del(17p) and/or TP53 mutation<sup>a</sup>






Prior BTKi, CIT, BCL2i, and PI3Ki therapy



Data cutoff date of 29 July 2022. Response status per iwCLL 2018 according to independent review committee assessment. <sup>a</sup>BTK C481 mutation status, del(17p), and TP53 mutation status were centrally determined and based on pre-treatment samples. <sup>b</sup>Patients with available mutation data who progressed on any prior BTKi.


#### Mato et al. ASH 2022, Abstract #961

#### **BRUIN CLL-321: Study Design**



Treatment was given in 28-day cycles. PFS assessed based on iwCLL2018. <sup>a</sup>Idelalisib dosed at 150mg PO BID. Day 1 of cycle 1, first dose of rituximab at 375 mg/m<sup>2</sup>, next 4 infusions at 500 mg/m<sup>2</sup> every 2 weeks, next 3 infusions at 500 mg/m<sup>2</sup> every 4 weeks. <sup>b</sup>Bendamustine (70 mg/m<sup>2</sup>) administered IV D1, D2 of cycles 1-6. <sup>c</sup>Day 1 of cycle 1, first dose of rituximab at 375 mg/m<sup>2</sup>, next 5 infusions day 1 of cycle 2 through cycle 6 at 500 mg/m<sup>2</sup>. <sup>d</sup>Eligible patients receiving investigator's choice of IdelaR/BR could crossover to receive pirtobrutinib monotherapy upon confirmation of PD by IRC per protocol. Abbreviations: BID, twice daily; BR, bendamustine + rituximab; cBTKi, covalent Bruton tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IdelaR, idelalisib + rituximab; IRC, Independent Review Committee; iwCLL, international workshop on chronic lymphocytic leukemia; mg, milligram; PD, progressive disease; PFS, progression-free survival; PO, by mouth; QD, once daily; R, randomized; SLL, small lymphocytic lymphoma. **Sharman, et al., ASH 2024, Abstract #886** 


#### **BRUIN CLL-321: IRC-Assessed Progression-free Survival**



\*nominal p-value. Abbreviations: BR, bendamustine + rituximab; CI, confidence interval; HR, hazard ratio (pirtobrutinib vs. IdelaR/BR); IdelaR, idelalisib + rituximab; IRC, Independent Review Committee; mo, months; PFS, progression-free survival.


Sharman, et al., ASH 2024, Abstract #886

## BRUIN CLL-321: Time to Next Treatment or Death in Venetoclax Naïve and Treated Patients



\*nominal p-value. Abbreviations: BR, bendamustine + rituximab; CI, confidence interval; HR, hazard ratio; IdelaR, idelalisib + rituximab; IRC, independent review committee; mo, months; TTNT, time to next treatment.

#### Sharman, et al., ASH 2024, Abstract #886



#### Overall survival follow-up limited and confounded by high rate of post-progression crossover

\*Defined as patients with investigator-defined PD events other than death. Abbreviations: BR, bendamustine + rituximab; CI, confidence interval; IdelaR, idelalisib + rituximab; IPCW, inverse-probability-of-censoring weighting; AFT, adjusted for treatment; mo, months; NE, not estimable; NR, not reached; OS, overall survival.


#### **BRUIN CLL-321: Adverse Events of Interest for Pirtobrutinib**

Adverse Events of Interest	Pirtobrutinib (n=116)	
	Any grade n (%)	Grade 3+ n (%)
Bleeding	25 (21.6)	4 (3.4)
Bruising	9 (7.8)	1 (0.9)
Petechiae and purpura	6 (5.2)	1 (0.9)
Hemorrhage	18 (15.5)	3 (2.6)
Anemia	24 (20.7)	13 (11.2)
Neutropenia	31 (26.7)	24 (20.7)
Thrombocytopenia	11 (9.5)	9 (7.8)
Infection	74 (63.8)	34 (29.3)
Infection without Covid-19	67 (57.8)	30 (25.9)
Atrial fibrillation and atrial flutter	3 (2.6) <sup>a</sup>	2 (1.7)
Hypertension	8 (6.9)	3 (2.6)

<sup>a</sup>2 of 3 patients with atrial fibrillation had a past medical history of atrial fibrillation

Overall pirtobrutinib AESI rates were comparable to those seen in the Phase 1/2 BRUIN Study<sup>5</sup>

#### **BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration** pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma





#### Eyre TA et al. ASCO 2023; Abstract TPS7583. Mato AR et al. ASH 2021; Abstract 3742.

.

# BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with CLL/SLL


#### BRUIN CLL-314 is a Randomized, Open-Label, Global, Phase 3 Study (NCT05254743)

#### **Key Inclusion Criteria**

- Confirmed diagnosis of CLL/SLL with requirements for therapy (as defined by iwCLL 2018<sup>2</sup> criteria)
- Treatment naïve (up to 30%) or pretreated with non-BTKi therapy
- ≥18 years of age and ECOG 0–2

#### **Stratification factors**

17p deletion (present vs not present)
Number of prior lines of therapy (0 vs 1 vs ≥2)



28-day continuous cycles, until progressive disease or unacceptable toxicity

#### **Primary Endpoints**

 To establish non-inferiority of pirtobrutinib versus ibrutinib by comparing the overall

response rate per iwCLL 20182 criteria as assessed by IRC


#### **Key Secondary Endpoints**

To determine the superiority of pirtobrutinib versus ibrutinib with respect to IRC-assessed event-free survival and progression-free survival



# BRUIN CLL-313: A phase 3 open-label, randomized study of pirtobrutinib versus bendamustine plus rituximab in untreated patients with CLL/SLL

#### BRUIN CLL-313 is a randomized, open-label, global phase 3 study (NCT05023980)



Status of IGHV mutation (mutated vs unmutated)

Rai stage (low / intermediate vs high)

 Patients in Arm B who have PD, as assessed by IRC, are allowed to crossover to Arm A



## **Cardiovascular Toxicity with BTKi**

ВТКі	Mechanism	Approved Indications (United States)	Key Trials	Cardiac Adve	rse Events
First Generation					
Irreversible covalent	Irreversible, covalent	CLL/SLL	RESONATE RESONATE-2 ILLUMINATE	Arrhythmia AF	
lbrutinib	binding to Cysteine-481	Waldenstrom's Macroglobulinemia Chronic Graft versus Host Disease (GVHD)		Hypertension:	9-23 %
				Major Bleeding:	3.9-10 %
Second Generation					
				AF Arrhythmia	9.4%
Acalabrutinib	Irreversible, covalent	CLL/SLL	ELEVATE T-N	VA	: 0.4 %
Acaiabi ucinib	binding to Cysteine-481	ne-481 Mantle Cell Lymphoma*	ELEVATE R-R	Hypertension:	9.4 %
				Major Bleeding:	4.5 %
	Irreversible, covalent	CLL/SLL Mantle cell lymphoma* Relapsed/refractory Marginal zone lymphoma** Waldenstrom's Macroglobulinemia	SEQUOIA ASPEN ALPINE	AF Arrhythmia	: 2-5 %
Zenukautinik				VA	: 0.2-0.8 %
Zanubrutinib	binding to Cysteine-481			Hypertension:	10-23.5 %
				Major Bleeding:	2.9-5.9 %
Third Generation					
Reversible			BRUIN		F: 3.9 %
	Reversible, non-covalent binding to ATP pocket	Relapsed or Refractory CLL/SLL Mantle Cell Lymphoma***		Arrhythmia N	A: NR
Pirtobrutinib				Hypertension:	2.3 %
				Major Bleeding	2.4 %



## **TRANSCEND CLL 004: Demographics & Baseline**

	DL2 + ibrutinib set (n = 51)	Total liso-cel + ibrutinib combination set (n = 56)
Median (range) age, y	65 (44-77)	65 (44-77)
Median (range) prior lines of systemic therapy	5 (1-13)	5 (1-13)
$\leq$ 3 prior therapies, n (%)	19 (37)	20 (36)
Prior BTKi, n (%)	51 (100)	56 (100)
Prior venetoclax, n (%)	39 (76)	42 (75)
Prior BTKi and venetoclax, n (%)	39 (76)	42 (75)
BTKi progression/venetoclax failure, <sup>a</sup> n (%)	28 (55)	31 (55)
High-risk cytogenetics, n (%)	50 (98)	55 (98)
Del(17p)	23 (45)	25 (45)
Mutated TP53	23 (45)	24 (43)
Unmutated IGHV	37 (73)	39 (70)
Complex karyotype <sup>b</sup>	25 (49)	29 (52)
Bulky disease (≥ 5 cm) per INV before LDC, <sup>c</sup> n (%)		
Yes	18 (35)	18 (32)
Unknown	4 (8)	5 (9)
Median (range) SPD per INV before LDC, <sup>d</sup> cm <sup>2</sup>	29 (1-218)	27 (1-218)
LDH $\geq$ ULN before LDC, n (%)	22 (43)	24 (43)
Received bridging therapy (in addition to ibrutinib), <sup>e</sup> n (%)	13 (25)	16 (29)

• Median (range) ibrutinib exposure was 34 days (15–188) before and 95 days (6–1517) after liso-cel in the total combination-treated set


• Liso-cel was manufactured for 63/65 (97%) patients in the leukapheresed set

- Median (range) time from leukapheresis to liso-cel availability was 25 (17–79) days (n = 62)

<sup>a</sup>Includes patients who progressed on a BTKi and met 1 of the following criteria: 1) discontinued venetoclax due to disease progression or intolerability and the patient's disease met indications for further treatment per iwCLL 2018 criteria or 2) failed to achieve an objective response within 3 months of initiating therapy; <sup>b</sup>At least 3 chromosomal aberrations; <sup>c</sup>At least 1 lesion with a longest diameter  $\geq$  5 cm; <sup>d</sup>Forty-seven patients at DL2 and 51 patients in the total combination-treated set had SPD measurements; <sup>e</sup>Included other anticancer therapies in addition to concurrent ibrutinib treatment given for disease control during liso-cel manufacturing. IGHV, immunoglobulin heavy-chain variable region; LDC, lymphodepleting chemotherapy; SPD, sum of the product of perpendicular diameters.


## Efficacy outcomes: response by investigator and uMRD4

- Median (IQR) on-study follow-up (including LTFU): 24.8 months (14.2–34.6)
- Median (range) time to first response: 1 month (0.9–6.0)
- Median (range) time to first CR/CRi: 3 months (0.9–12.1)




<sup>a</sup>Forty-nine patients (22 with CR/CRi) were evaluable for MRD in marrow.

## Progression-free survival by best overall response at DL2




Data on KM curves are expressed as median (95% CI). No formal landmarking analyses were conducted.

## **Overall survival by best overall response at DL2**



Data on KM curves are expressed as median (95% CI). No formal landmarking analyses were conducted.

## Safety: incidence of CRS and NEs



<sup>a</sup>Summed percentages for grouped grades within each graph may not equal the any-grade percentage due to rounding; <sup>b</sup>CRS was graded based on Lee 2014 criteria; <sup>c</sup>NEs were defined as -INV-identified neurological AEs related to liso-cel.

#### Agenda

#### Module 1: Selection and Sequencing of Therapy for Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda

Module 2: First-Line Therapy for CLL — Dr Coombs

Module 3: Novel Agents and Strategies for RR CLL — Dr Wierda

Module 4: ASCO and EHA 2025



Regulatory and reimbursement issues aside, outside of a clinical trial, have you or would you administer a BTKi inhibitor in combination with venetoclax +/- an anti-CD20 antibody as first-line treatment for CLL? If you were going to administer a BTKi in combination with venetoclax +/- an anti-CD20 antibody as first-line treatment for CLL, which would be your preferred BTKi?

	BTK inhibitor + venetoclax +/- anti-CD20 antibody	Preferred BTK inhibitor
Dr Coombs	I have	Acalabrutinib
Dr Wierda	I have	Ibrutinib
Dr Allan	I have	Zanubrutinib
Dr Davids	I have	Acalabrutinib
Dr Sharman	I haven't but would for the right patient	Acalabrutinib
Dr Siddiqi	I haven't but would for the right patient	Zanubrutinib

Regulatory and reimbursement issues aside, in what specific clinical situations would you prefer to administer the time-limited regimen of a BTK inhibitor in combination with venetoclax with or without an anti-CD20 antibody as first-line therapy for CLL?

Dr Coombs	AV: pt desiring time limited but prefers all oral AVO: pt desiring time limited with higher-risk markers
Dr Wierda	This is my preferred first-line treatment approach
Dr Allan	Bulky unmutated IGHV del(17p) or del(11q) CLL
Dr Davids	AV: older pts/those with comorbidities and low-risk genetics AVO: younger or fit pts/those with higher-risk genetics desiring time-limited therapy
Dr Sharman	Bulky nodes, higher risk for TLS, patient preference
Dr Siddiqi	Younger patient, high-risk cytogenetics, desire for fixed-duration therapy but not keen on multiple infusions

AV = acalabrutinib and venetoclax; AVO = acalabrutinib, venetoclax and obinutuzumab; TLS = tumor lysis syndrome



Regulatory and reimbursement issues aside, and assuming equal access to acalabrutinib, zanubrutinib and pirtobrutinib, in general, which BTK inhibitor would you prefer to administer as first-line treatment for CLL?





<u>Regulatory and reimbursement issues aside</u>, what would be your preferred initial regimen for a patient with CLL and an <u>IGHV mutation and no del(17p) or TP53</u> <u>mutation</u> requiring treatment?

	60-year-old patient	80-year-old patient
Dr Coombs	Venetoclax + obinutuzumab	Venetoclax + obinutuzumab
Dr Wierda	Venetoclax + obinutuzumab	Venetoclax + obinutuzumab
Dr Allan	Venetoclax + obinutuzumab	Zanubrutinib
Dr Davids	Venetoclax + obinutuzumab	Venetoclax + obinutuzumab
Dr Sharman	Venetoclax + obinutuzumab	Venetoclax + obinutuzumab
Dr Siddiqi	Venetoclax + obinutuzumab	Venetoclax + obinutuzumab

<u>Regulatory and reimbursement issues aside</u>, what would be your preferred initial regimen for a patient with CLL and <u>no IGHV mutation or del(17p) or TP53 mutation</u> requiring treatment?

	60-year-old patient	80-year-old patient
Dr Coombs	Venetoclax + obinutuzumab	Zanubrutinib
Dr Wierda	Ibrutinib + venetoclax	Acalabrutinib + venetoclax; acalabrutinib + venetoclax + obinutuzumab
Dr Allan	Zanubrutinib + venetoclax + obinutuzumab	Zanubrutinib
Dr Davids	Venetoclax + obinutuzumab	Venetoclax + obinutuzumab
Dr Sharman	Acalabrutinib + obinutuzumab	Zanubrutinib
Dr Siddiqi	Venetoclax + obinutuzumab	Zanubrutinib

<u>Regulatory and reimbursement issues aside</u>, what would be your preferred initial regimen for a patient with CLL and <u>no IGHV mutation but with a del(17p) or TP53</u> <u>mutation</u> requiring treatment?

	60-year-old patient	80-year-old patient
Dr Coombs	Zanubrutinib	Zanubrutinib
Dr Wierda	Ibrutinib + venetoclax	Acalabrutinib or zanubrutinib
Dr Allan	Zanubrutinib + venetoclax + obinutuzumab → zanubrutinib	Zanubrutinib
Dr Davids	Zanubrutinib	Zanubrutinib
Dr Sharman	Zanubrutinib + venetoclax	Zanubrutinib
Dr Siddiqi	Zanubrutinib + venetoclax	Zanubrutinib

# First-line therapy for chronic lymphocytic leukemia

Callie Coombs, MD Associate Clinical Professor University of California Irvine

## What do the guidelines say?


SUGGESTED TREATMENT REGIMENS<sup>a,b,c,d</sup> CLL/SLL Without del(17p)/*TP53* Mutation (alphabetical by category)


	FIRST-LINE THERAPY <sup>e</sup>	
Preferred Regimens	Other Recommended Regimens	Useful in Certain Circumstances
<ul> <li>BCL2i-containing regimens <ul> <li>Venetoclax<sup>f,h</sup> + obinutuzumab (category 1)</li> <li>Venetoclax<sup>f,h</sup> + acalabrutinib ± obinutuzumab (category 1)</li> <li>cBTKi-based regimens</li> <li>Acalabrutinib<sup>f,g</sup> ± obinutuzumab (category 1)</li> <li>Zanubrutinib<sup>f,g</sup> (category 1)</li> </ul> </li> </ul>	<ul> <li>BCL2i-containing regimen</li> <li>Venetoclax<sup>f,h</sup> + ibrutinib<sup>f,g</sup></li> <li>cBTKi-based regimen</li> <li>Ibrutinib<sup>f,g,i</sup> (category 1)</li> </ul>	<ul> <li>Consider for IGHV-mutated CLL in patients aged &lt;65 y without significant comorbidities</li> <li>FCR (fludarabine, cyclophosphamide, rituximab)<sup>j,k</sup></li> <li>cBTKi-based regimen</li> <li>Ibrutinib<sup>f,g</sup> + anti-CD20 mAb (category 2B)<sup>I</sup></li> <li>Consider when cBTKi and BCL2i are not available or contraindicated or rapid disease debulking needed</li> <li>Bendamustine<sup>m</sup> + anti-CD20 mAb<sup>I,n</sup></li> <li>Obinutuzumab ± chlorambucil<sup>o</sup></li> <li>High-dose methylprednisolone (HDMP) + anti-CD20 mAb<sup>I</sup> (category 2B; category 3 for patients &lt;65 y without significant comorbidities)</li> </ul>

 Guidelines for patients with 17p/TP53 mutation are similar but advise against CIT (and no category 1 regimens in first-line)


## Ibrutinib provides **long-term** disease control

• With up to 10-years of follow up from RESONATE-2 trial demonstrates median PFS of 8.9 years for ibrutinib-treated patients compared to 1.3 years for chlorambucil-treated patients






**OS Benefit Was Sustained for Patients Receiving Ibrutinib** 




Clb, chlorambucil.

# Ibrutinib is no longer a favored BTKi due to toxicity profile




ELEVATE-RR: Acalabrutinib has non-inferior efficacy to ibrutinib in high-risk relapsed population, but superior safety Safety HTN



ALPINE: Zanubrutinib has superior efficacy vs. ibrutinib in all-comer relapsed population, also superior safety afib/flutter, but similar HTN


Byrd et al. JCO 2021 and Brown et al. ASH 2023

#### **ELEVATE TN: Study Design**



 Interim analysis was planned based on events (after occurrence of ~111 IRC-assessed PFS events in the combination therapy arms) or after 24 months if the required number of events was not met by this time


#### Median PFS was significantly higher for A-containing arms vs O+Clb



Median PFS was significantly higher for A+O vs A

<sup>a</sup>Hazard ratio based on stratified Cox proportional-hazards model. <sup>b</sup>*P*-value based on stratified log-rank test. Sharman et al. ASH 2023

#### SEQUOIA study design




- CR/CRi confirmed via bone marrow biopsy
- · AEs documented until PD or start of next CLL therapy

• Safety was assessed in all pts who received ≥1 dose of treatment

- Clinical outcomes (correlated with baseline prognostic and predictive markers)
- Safety

## 5-year SEQUOIA follow up




241 238 234 230 228 224 219 214 208 205 201 200 195 192 190 183 178 164 153 89 81 19 Zanubrutinib 19 2 1 0

Shadman M et al. JCO 2024

BR

## Phase III CLL14 Study: 6-Year Update





• Reformatted from Al-Sawaf et. al. EHA 2023. Presentation ID S145

## Venetoclax in frontline setting: CLL14 trial

Updates from 6 year follow up:


- Median PFS reached: 76.2 months
- Median PFS for TP53 aberrant pts: 51.9 months
- Median PFS for unmut IGHV pts: 64.8 months





#### GAIA/CLL13 Study Design for Fit Patients With CLL

Chemoimmunotherapy (**FCR/BR**) vs **R**ituximab + **V**enetoclax vs Obinutuzumab (**G**) + **V** vs **G** + **I**brutinib + **V** Recruitment in 10 countries (DE, AT, CH, NL, BE, DK, SE, FI, IE, IL)



Eichhorst B et al. 2022 EHA; Abstract LB2365.


## 4-year follow up of CLL13 trial support VOcontaining regimen superiority

Α

Venetoclax-obinutuzumab-ibrutinib vs chemoimmunotherapy: HR 0·30 (97·5% Cl 0·19–0·47), log-rank p<0·0001 Venetoclax-obinutuzumab-ibrutinib vs venetoclax-rituximab: HR 0·38 (97·5% Cl 0·24–0·59), log-rank p<0·0001 Venetoclax-obinutuzumab-ibrutinib vs venetoclax-obinutuzumab: HR 0·63 (97·5% Cl 0·39–1·02), log-rank p=0·031

Venetoclax-obinutuzumab vs chemoimmunotherapy: HR 0.47 (97.5% CI 0.32–0.69), log-rank p<0.0001 Venetoclax-obinutuzumab vs venetoclax-rituximab: HR 0.57 (97.5% CI 0.38–0.84), log-rank p=0.0011

Venetoclax-rituximab vs chemoimmunotherapy: log-rank p=0.10, proportional hazards assumption not satisfied




Unmutated IGHV only

В


Venetoclax-obinutuzumab-ibrutinib vs chemoimmunotherapy: HR 0·27 (95% Cl 0·17–0·42), p<0·0001 Venetoclax-obinutuzumab-ibrutinib vs venetoclax-rituximab: HR 0·40 (95% Cl 0·25–0·63), p<0·0001 Venetoclax-obinutuzumab-ibrutinib vs venetoclax-obinutuzumab: HR 0·58 (95% Cl 0·36–0·94), p=0·025

Venetoclax-obinutuzumab vs chemoimmunotherapy: HR 0.45 (95% Cl 0.31–0.66), p<0.0001 Venetoclax-obinutuzumab vs venetoclax-rituximab: HR 0.65 (95% Cl 0.45–0.96), p=0.030

Venetoclax-rituximab vs chemoimmunotherapy: log-rank p=0.015, proportional hazards assumption not satisfied




# Rationale to combine BTKi with BCL2i



1. Lu P et al. *Blood Cancer J.* 2021; 11:39; 2. Deng J et al. *Leukemia.* 2017; 31:2075-2084; 3. Herman ES et al. *Clin Cancer Res.* 2015; 21:4642-4651; 4. Burger JA et al. *Leukemia.* 2020;34:787-798; 5. Shanafelt T et al. *N Engl J Med.* 2019;381:432-443; 6. Cervantes-Gomez, F. et al. *Clin. Cancer Res.* 2015; 21:3705–3715; 7. Slinger E, et al. *Blood.* 2017; 130: 3018-3018; 8. Haselager MV, et al. *Blood.* 2020 ;136:2918-2926; 9. Slinger E et al. Leukemia. 2017 Dec;31(12):2601-2607.


## AMPLIFY: Combination cBTKi and BCL2i Therapy in 1L CLL



Median PFS was NR for AV and AVO, and was 47.6 mo for FCR/BR


• Brown, JR et. al. Blood. 2024; 144: abstract 1009.

## **AMPLIFY: Secondary Endpoints**



#### uMRD Rates (Flow Cytometry [<10<sup>-4</sup>] in PB)

Key secondary endpoint timing: cycle 9, day 1 (AV arm), cycle 10, day 1 (AVO arm), and cycle 6, day 1 plus 12 weeks (FCR/BR)




• Brown, JR et. al. Blood. 2024; 144: abstract 1009.

## **Overall Survival**


#### OS Prolonged With AV vs FCR/BR

#### OS Prolonged With AV and AVO vs FCR/BR (COVID-19 Deaths Censored)





COVID-19 deaths: 10 (AV), 25 (AVO), 21 (FCR/BR)

# AVO in patients with TP53 aberrations?




# AVO remains highly effective in high-risk patients






# MAJIC Study Design




Ryan, C. E., Davids, M. S., Hermann, R., Shahkarami, M., Biondo, J., Abhyankar, S., ... Roeker, L. E. (2022). MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Future Oncology, 18(33), 3689–3699.


## BGB-11417-101: Phase 1/2 Evaluating Sonrotoclax + Zanu



- 8 to 12 weeks of zanubrutinib monotherapy was given prior to sonrotoclax dosing (12 weeks if high tumor burden)
- Sonrotoclax was dosed orally, once daily, using a weekly or daily ramp-up schedule to reach the target dose




#### **Best Blood MRD**<sup>a</sup>



### More to come on Zanu + Sonrotoclax in the 1L

#### **CELESTIAL-TNCLL Study Design**



<sup>a</sup> Defined as CR or CR with incomplete recovery. <sup>b</sup> At[<10<sup>4</sup> sensitivity at the first post-treatment follow-up based on next-generation sequencing by clonoSEQ<sup>®</sup> and flow cytometry. BM, bone [marrow]; CRR, complete [response] rate; DOR, duration of response; INV, assessed by investigator; IRC, assessed by independent review committee; PB, [peripheral] blood, R, randomized; TN, treatment naive; uMRD4, undetectable measurable residual disease.

## Approved Treatments in Frontline CLL: Pros and Cons

lbrutinib	Acalabrutinib/Zanubrutinib	Venetoclax + Obinutuzumab (VO), Acala-Ven (AV), Acala-Ven-Obin (AVO)		
<ul> <li>Pro</li> <li>Longest follow-up</li> <li>Median PFS 8.9 years from RESONATE-2 trial</li> <li>Once daily oral drug</li> </ul> • Con <ul> <li>Indefinite duration</li> <li>Low CR/uMRD</li> <li>Atrial fibrillation, bleeding</li> </ul>	<ul> <li>Pro         <ul> <li>Reduced off-target effects lead to improved safety vs. ibrutinib</li> <li>Zanubrutinib with superior efficacy vs. ibrutinib (in relapsed setting)</li> </ul> </li> <li>Con         <ul> <li>Shorter follow-up</li> <li>Indefinite duration</li> <li>Low CR/uMRD</li> <li>Atrial fibrillation, bleeding</li> </ul> </li> </ul>	<ul> <li>Pro <ul> <li>Time-limited</li> <li>High CR/uMRD (VO/AVO likely &gt; AV)</li> </ul> </li> <li>Con <ul> <li>Shorter follow-up</li> <li>TLS logistics</li> <li>IV administration of obinutuzumab aside from AV</li> <li>Neutropenia, infection risk</li> <li>Shorter remissions in del(17p)/TP53-m with VO (not included in AMPLIFY trial)</li> </ul> </li> </ul>		

• Barr PM, et al. Blood Adv. 2022;6:3440-3450. O'Brien SM, et al. Front Oncol. 2021; 11: 720704. Brown JR, et al. N Engl J Med. 2025;392:748-762.

# Conclusions

- There are several effective first-line therapies in CLL
- Likely will not have a "one-size-fits-all" first-line regimen
- Shared decision making hugely important to select the best therapy for any given patient

### Agenda

Module 1: Selection and Sequencing of Therapy for Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda

**Module 2:** First-Line Therapy for CLL — Dr Coombs

Module 3: Novel Agents and Strategies for RR CLL — Dr Wierda

Module 4: ASCO and EHA 2025



# **New Agents for Relapsed/Refractory CLL**

## Old targets:

- BTK only degrader (bexobrutideg [NX-5948]; BGB-16673; ABBV-101)
- ncBTKi (nemtabrutinib; TT-01488; LP-168)
- ngBCL2i (lisaftoclax; sonrotoclax; ABBV-453)
- CD20xCD3 bispecifics (mosunetuzumab; epcoritamab; glofitamab; odronextamab)

## • New targets:


- BCL-xL/BCL-2 (LP-118)
- PKC $\beta$  inhibitor (MS-553)
- MALT1 (ABBV-525)
- ROR1 (xCD3 bispecific; CAR-T cells)

### **Epcoritamab in CLL: Deep Responses Across Subgroups**

		C1 OPT mFU: 2.9 months					
Response, n (%)	Full Analysis Set N=23	Response Evaluable n=21	<i>TP53</i> Aberration n=15	<i>IGHV</i> Unmutated n=16	Double Exposedª n=19	Response Evaluable n=10	
Overall response <sup>b</sup>	14 (61)	14 (67)	10 (67)	10 (63)	10 (53)	6 (60)	
Complete response	9 (39)	9 (43)	5 (33)	7 (44)	7 (37)	1 (10)	
Partial response	5 (22)	5 (24)	5 (33)	3 (19)	3 (16)	5 (50)	
Stable disease	4 (17)	4 (19)	2 (13)	3 (19)	4 (21)	2 (20)	
Progressive disease	1 (4)	1 (5)	1 (7)	0	1 (5)	1 (10)	
<ul> <li>With limited follow-up, the C1 OPT regimen does not appear to affect epcoritamab efficacy</li> </ul>		EXP MRD Neg	EXP MRD Negativity, n/n (%) <sup>c</sup>		uMRD6 <sup>d</sup>		
		Overall respon	Overall response <sup>b</sup>		8/12 (67)		
• uMRD4 in PBMCs v	vas observed in r	nost	Complete re	Complete response		6/7 (86)	
responders, includin	g all patients wit	h CR who	Partial resp	onse	2/5 (40)	2/5 (40)	
were tested for MRD		Full analysis se	et	9/23 (39)	8/23 (35)		

Four patients (*TP53* aberration, n=2; *IGHV* unmutated, n=3; double exposed, n=4) in EXP and 1 in C1 OPT shown above were not evaluable or had no assessment, including 3 in EXP (*TP53* aberration, n=2; *IGHV* unmutated, n=2; double exposed, n=3) and 1 in C1 OPT who died without postbaseline assessment. <sup>a</sup>Patients previously treated with both a BTK inhibitor and a BCL-2 inhibitor. <sup>b</sup>Response assessment according to iwCLL criteria. <sup>c</sup>Patients evaluated for MRD had at least 1 on-treatment MRD result and were not MRD negative at baseline. MRD was only evaluated in patients with CR or PR. <sup>d</sup>Two of 3 evaluated patients had uMRD6 in bone marrow at or shortly after the first CR assessment. mFU, median follow-up.

### **Epcoritamab in CLL: Treatment-Emergent AEs (>20%) in EXP**




Patients With ≥1 Event, n (%)	EXP N=23
Anemia	15 (65)
At study entry	14 (61)
In first 8 weeks	15 (65)
Thrombocytopenia	15 (65)
At study entry	14 (61)
In first 8 weeks <sup>a</sup>	14 (61)
Neutropenia	11 (48)
At study entry	1 (4)
In first 8 weeks <sup>b</sup>	11 (48)

- TEAEs were primarily low grade (G1-2)
- TEAEs led to treatment discontinuation in 5 patients from EXP and 1 patient from C1 OPT
- 4 fatal TEAEs<sup>e</sup> occurred in EXP; none occurred in C1 OPT


<sup>a</sup>Combined term includes thrombocytopenia and decreased platelet count. <sup>b</sup>Combined term includes neutropenia, decreased neutrophil count, and febrile neutropenia. Three patients had febrile neutropenia (EXP, n=2 [grades 1 and 3]; C1 OPT, n=1 [grade 3]). <sup>c</sup>Combined term includes injection-site reaction, bruising, erythema, rash, and swelling. <sup>d</sup>Combined term includes COVID-19 and COVID-19 pneumonia. <sup>e</sup>Fatal TEAEs were pneumonia (n=2), sepsis (n=1), and squamous cell carcinoma of the skin (n=1); 1 case of pneumonia was considered related to epcoritamab.

### **Epcoritamab in CLL: Progression-Free and Overall Survival in EXP**



• Median PFS was 12.8 months (95% CI, 5.4–17.1); median OS was not reached (95% CI, 8.6 months–NR)

### Background Novel BTK degrader NX-5948 addresses current unmet need in CLL treatment



- The current standard of care in CLL focuses on utilizing the inhibitors of two key signaling pathways – BTK and BCL2
- Unmet need still exists in the CLL treatment landscape:
  - Covalent and non-covalent BTKi resistance mutations<sup>1</sup> are found in more than half of patients who progress on BTKi therapies<sup>2</sup>
  - Some mutations in *BTK* can maintain intact B-cell receptor signaling through a scaffolding function of BTK<sup>3</sup>
  - The number of BCL2i refractory and double (BTKi/BCL2i) refractory patients is growing<sup>4</sup>
- Novel BTK degrader NX-5948 offers an additional treatment modality:
  - Can overcome treatment-emergent BTKi resistance mutations<sup>5</sup> and disrupt BTK scaffolding<sup>3,5</sup>

#### BCL2, B-cell lymphoma 2; BCL2i, BCL2 inhibitor; BTK, Bruton's tyrosine kinase; BTKi, BTK inhibitor; CLL, chronic lymphocytic leukemia

#### References

- 1. Noviski et al. 20th Biennial International Workshop on CLL Meeting, Boston, MA. October 6-9, 2023
- 2. Molica et al. 66th ASH Annual Meeting, December 7–10, 2024
- 3. Montoya et al. Science 2024;383
- 4. Hayama and Riches. Onco Targets 2024;17

5. Linton K, et al. Oral presentation at European Hematology Association Hybrid Congress; 16 June 2024

#### Shah, et al., ASH 2024, Abstract #884

### NX-5948-301 (Bexobrutideg): Safety Profile TEAEs in $\geq$ 10% of overall population or Grade $\geq$ 3 TEAEs or SAEs in >1 patient

	Patients	with CLL/SLL	(n=60)	Overall population (N=125)			
<b>TEAEs,</b> n (%)	Any grade	Grade ≥3	SAEs	Any grade	Grade ≥3	SAEs	
Purpura/contusion <sup>a</sup>	22 (36.7)	_	_	42 (33.6)	_	_	
Fatigue <sup>b</sup>	16 (26.7)	-	_	29 (23.2)	2 (1.6)	_	
Petechiae	16 (26.7)	_	-	28 (22.4)	-	-	
Thrombocytopenia	10 (16.7)	1 (1.7)	-	26 (20.8)	7 (5.6)	-	
Rash <sup>d</sup>	14 (23.3)	1 (1.7)	1 (1.7)	24 (19.2)	2 (1.6)	1 (0.8)	
Neutropenia <sup>e</sup>	14 (23.3)	11 (18.3)	-	23 (18.4)	18 (14.4)	-	
Anemia	11 (18.3)	4 (6.7)	-	21 (16.8)	10 (8.0)	_	
Headache	10 (16.7)	_	_	21 (16.8)	1 (0.8)	1 (0.8)	
COVID-19 <sup>f</sup>	10 (16.7)	_	_	19 (15.2)	2 (1.6)	2 (1.6)	
Diarrhea	12 (20.0)	1 (1.7)	_	18 (14.4)	1 (0.8)	_	
Cough	9 (15.0)	_	_	16 (12.8)	1 (0.8)	_	
Pneumonia <sup>g</sup>	4 (6.7)	2 (3.3)	2 (3.3)	10 (8.0)	6 (4.8)	6 (4.8)	
Lower respiratory tract infection	3 (5.0)	1 (1.7)	1 (1.7)	9 (7.2)	3 (2.4)	2 (1.6)	
Fall	1 (1.7)	1 (1.7)	1 (1.7)	8 (6.4)	2 (1.6)	2 (1.6)	
Hypertension	2 (3.3)	1 (1.7)	_	7 (5.6)	5 (4.0)	_	
Hyponatremia	_	_	-	3 (2.4)	2 (1.6)	_	
Pulmonary embolism	1 (1.7)	1 (1.7)	1 (1.7)	2 (1.6)	2 (1.6)	2 (1.6)	
Subdural hematoma	1 (1.7)	_	1 (1.7)	2 (1.6)	1 (0.8)	2 (1.6)	

- Tolerable safety profile consistent with prior disclosures
- 1 case of Grade 1 AFib in a CLL patient with pre-existing AFib
- 6 TEAEs resulted in drug discontinuation (1 CLL; 5 NHL)
- 2 Grade 5 AEs (1 pulmonary embolism; 1 case pending) deemed not related to NX-5948

<sup>a</sup>Purpura/contusion includes episodes of contusion or purpura; <sup>b</sup>Fatigue was transient; <sup>c</sup>Aggregate of 'thrombocytopenia' and 'platelet count decreased'; <sup>d</sup>Aggregate of 'rash' and 'rash maculopapular' and 'rash pustular'; <sup>e</sup>Aggregate of 'neutrophil count decreased' or 'neutropenia'; <sup>f</sup>Aggregate of 'COVID-19' and 'COVID-19 pneumonia'; <sup>g</sup>Aggregate of 'pneumonia' and 'pneumon

AE, adverse event; AFib, atrial fibrillation; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin's lymphoma; SAE, serious adverse event; SLL, small lymphocytic lymphoma; TEAE, treatment emergent AE

# NX-5948-301 (Bexobrutideg): Overall Response Assessment

Response rate deepens with longer time on treatment

CLL response-evaluable patients	Primary ORR analysis <sup>b</sup> ≥1 response assessment(s) at 8 weeks (n=49) <sup>c</sup>	Exploratory ORR analysis <sup>b</sup> ≥2 response assessments at 16 weeks (n=38) <sup>c</sup>
<b>Objective response rate (ORR)</b> , <sup>a</sup> % (95% Cl)	75.5 (61.1–86.7)	84.2 (68.7–94.0)

#### Best response, n (%)

CR	0 (0.0)	0 (0.0)
PR	36 (73.5)	32 (84.2)
PR-L	1 (2.0)	0 (0.0)
SD	10 (20.4)	4 (10.5)
PD	2 (4.1)	2 (5.3)

<sup>a</sup>Objective response rate includes CR + PR + PR-L

<sup>b</sup>Patients who progressed prior to their first response assessment and patients who discontinued for any reason after their first response assessment are included in the denominators <sup>c</sup>Patients without identified target lesion(s) at baseline are evaluated as disease-evaluable per iwCLL criteria, while they may not be represented in waterfall plot

#### BGB-16673: Overall Response Rate Significant Responses, Particularly at 200 mg Dose Level


#### CaDAnCe-101: R/R CLL/SLL

	50 mg (n=1)	100 mg (n=5)	200 mg (n=16)	350 mg (n=15)	500 mg (n=12)	Total <sup>a</sup> (N=49)
Best overall response, n (%)		-				
CR/CRi	0	1 (20.0)	1 (6.3)	0	0	2 (4.1)
PR <sup>b</sup>	1 (100)	3 (60.0)	12 (75.0)	10 (66.7)	7 (58.3)	33 (67.3)
PR-L	0	0	2 (12.5)	0	1 (8.3)	3 (6.1)
SD	0	1 (20.0)	0	1 (6.7)	4 (33.3)	6 (12.2)
PD	0	0	1 (6.3)	1 (6.7)	0	2 (4.1)
Discontinued prior to first assessment	0	0	0	3 (20.0)	0	3 (6.1)
ORR, n (%) <sup>c</sup>	1 (100)	4 (80.0)	15 (93.8)	10 (66.7)	8 (66.7)	38 (77.6)
Disease control rate, n (%) <sup>d</sup>	1 (100)	5 (100)	15 (93.8)	11 (73.3)	12 (100)	44 (89.8)
Time to first response, median (range), months <sup>e</sup>	2.9 (2.9-2.9)	4.2 (2.8-6.2)	2.9 (2.6-8.3)	2.8 (2.6-8.3)	2.8 (2.6-8.3)	2.8 (2.6-8.3)
Time to best response, median (range), months	2.9 (2.9-2.9)	5.6 (2.8-11.1)	3.4 (2.6- 13.8)	5.6 (2.6-8.3)	4.2 (2.6-8.6)	3.6 (2.6- 13.8)
Duration of exposure, median (range), months	26.4 (26.4-26.4)	13.8 (13.6-18.6)	10.6 (2.9-18.9)	10.3 (0.2-16.8)	9.3 (6.8-15.4)	10.4 (0.2-26.4)

<sup>a</sup>Efficacy-evaluable population. <sup>b</sup>Out of 33 patients with PR, 8 achieved all nodes normalized. <sup>c</sup>Includes best overall response of PR-L or better. <sup>d</sup>Includes best overall response of SD or better. <sup>e</sup>In patients with a best overall response of PR-L or better. CR=complete response, CR=complete response with incomplete marrow recovery, ORR=overall response rate, PD=progressive disease, PR=partial response, PR-L=partial response with lymphocytosis, SD=stable disease.

### **BGB-16673: Progression-Free Survival**

#### CaDAnCe-101: R/R CLL/SLL



Data cutoff: September 2, 2024. PFS=progression-free survival.

# Conclusions

- Treatment for relapsed disease directed by prior treatment, duration of last remission, and clinical resistance to targeted agent(s)
- Refractory disease remains unmet need promising agents in development
  - Alternative targeted therapies
  - CD19-CAR T-cells
  - Bispecific antibodies

### Agenda

Module 1: Selection and Sequencing of Therapy for Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda

**Module 2:** First-Line Therapy for CLL — Dr Coombs

**Module 3:** Novel Agents and Strategies for RR CLL — Dr Wierda

Module 4: ASCO and EHA 2025



SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Tam C et al.

ASCO 2025; Abstract 7011.

RAPID ORAL ABSTRACT SESSION | SATURDAY, MAY 31 | 8:12 AM CT



**Combination of zanubrutinib (zanu) + venetoclax** (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D.

Shadman M et al.

ASCO 2025; Abstract 7009.

RAPID ORAL ABSTRACT SESSION | SATURDAY, MAY 31 | 8:00 AM CT



Impact of venetoclax-based therapies on autoimmune cytopenias in patients with chronic lymphocytic leukemia: Final analysis of a multicenter study conducted by ERIC. Vitale C et al. EHA 2025; Abstract S157

Updated efficacy and safety of the bruton tyrosine kinase (BTK) degrader BGB-16673 In patients (Pts) with relapsed or refractory (R/R) CLL/SLL: Results from the ongoing phase (Ph) 1 CADANCE-101 study.

Scarfò L et al. EHA 2025; Abstract S158

Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL demonstrate deep and durable responses.

Cheah CY et al.

EHA 2025; Abstract S159

### EHA 2025 | ORAL PRESENTATION SESSION | SUNDAY, JUNE 15



## Data + Perspectives: Clinical Investigators Discuss the Current and Future Clinical Care of Patients with HER2-Positive Gastrointestinal Cancers

A CME Symposium Held in Conjunction with the 2025 ASCO<sup>®</sup> Annual Meeting

Sunday, June 1, 2025 7:00 PM – 8:30 PM CT (8:00 PM – 9:30 PM ET)

> Faculty Haley Ellis, MD Sara Lonardi, MD Kanwal Raghav, MD, MBBS

Moderator Christopher Lieu, MD



## Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Ovarian and Endometrial Cancer

A CME Symposium Held in Conjunction with the 2025 ASCO<sup>®</sup> Annual Meeting

## Sunday, June 1, 2025 7:00 PM - 9:00 PM CT (8:00 PM - 10:00 PM ET)Faculty Joyce F Liu, MD, MPH David M O'Malley, MD Ritu Salani, MD, MBA **Alessandro D Santin, MD Moderator** Shannon N Westin, MD, MPH, FASCO, FACOG



## Thank you for joining us!

Please take a moment to complete the survey currently up on Zoom. Your feedback is very important to us. The survey will remain open for 5 minutes after the meeting ends.

Information on how to obtain CME credit is provided in the Zoom chat room. Attendees will also receive an email in 1 to 3 business days with these instructions.

